Drug
Vobramitamab Duocarmazine
Vobramitamab Duocarmazine: highest development phase Phase 2, developed by MacroGenics. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- MacroGenics
Trials
| Drug | Phase | Indication |
|---|---|---|
| vobramitamab duocarmazine 2.0 mg (Arm A) NCT05551117 | Phase 2 | Castration-Resistant Prostatic Cancer |
| vobramitamab duocarmazine NCT03729596 | Phase 1/2 | Squamous Cell Carcinoma of Head and Neck |
| vobramitamab duocarmazine NCT05293496 | Phase 1 | Advanced Solid Tumor |
Latest
Follow Vobramitamab Duocarmazine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.